FN3K and age-related macular degeneration: We studied the potential of recombinant FN3K treatment in the disruption of AGE-related retinal autofluorescence (AF), assessed its effects after treatment of tissue sections originating from AMD patients and evaluated its effects on drusenoid material and lesions after intravitreal injection of post-mortem murine and human eyes.